|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
DK2470644T3
(en)
|
2009-08-24 |
2017-01-16 |
Baylor College Medicine |
GENERATION OF CTL LINES WITH SPECIFICITY AGAINST MORE TUMOR ANTIGEN OR MORE
|
|
CN105648056A
(zh)
*
|
2010-05-14 |
2016-06-08 |
综合医院公司 |
鉴定肿瘤特异性新抗原的组合物和方法
|
|
RS64230B1
(sr)
*
|
2011-05-24 |
2023-06-30 |
BioNTech SE |
Individualizovane vakcine protiv kancera
|
|
RS59369B1
(sr)
*
|
2011-05-24 |
2019-11-29 |
Biontech Rna Pharmaceuticals Gmbh |
Individualizovane vakcine protiv kancera
|
|
EP2757153B1
(en)
*
|
2011-08-02 |
2019-07-03 |
The University of Tokyo |
Method for assessing myelodysplastic syndrome or myeloid tumor predisposition, polypeptide and antibody therefor, and candidate screening method for therapeutic drug or prophylactic drug therefor
|
|
US20130164746A1
(en)
*
|
2011-09-29 |
2013-06-27 |
Davide Rossi |
Mutations in SF3B1 and Chronic Lymphocytic Leukemia
|
|
US20140364439A1
(en)
*
|
2011-12-07 |
2014-12-11 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
US20150010519A1
(en)
|
2012-02-09 |
2015-01-08 |
Baylor College Of Medicine |
Pepmixes to generate multiviral ctls with broad specificity
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
CA2886218A1
(en)
|
2012-05-25 |
2013-11-28 |
Phosimmune, Inc. |
Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
|
|
MX364370B
(es)
*
|
2012-07-12 |
2019-04-24 |
Persimmune Inc |
Vacunas contra el cancer personalizadas y terapias de celulas inmunes adoptivas.
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
EP3718556A3
(en)
|
2012-08-31 |
2020-12-30 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
AU2013312529A1
(en)
|
2012-09-05 |
2015-04-16 |
The University Of Birmingham |
Target peptides for colorectal cancer therapy and diagnostics
|
|
WO2014052707A2
(en)
|
2012-09-28 |
2014-04-03 |
The University Of Connecticut |
Identification of tumor-protective epitopes for the treatment of cancers
|
|
AU2013351542B2
(en)
*
|
2012-11-28 |
2018-08-09 |
BioNTech SE |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
SG10201710473VA
(en)
|
2013-02-22 |
2018-02-27 |
Curevac Ag |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
DK3292873T3
(da)
|
2013-02-22 |
2019-06-03 |
Curevac Ag |
Kombination af vaccination og hæmning af PD-1-vejen
|
|
WO2014160132A1
(en)
|
2013-03-14 |
2014-10-02 |
The Johns Hopkins University |
Nanoscale artificial antigen presenting cells
|
|
CA3137846A1
(en)
*
|
2013-04-07 |
2014-10-16 |
The Broad Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
US20160310584A1
(en)
*
|
2013-12-06 |
2016-10-27 |
The Broad Institute Inc. |
Formulations for neoplasia vaccines
|
|
EP3082853A2
(en)
*
|
2013-12-20 |
2016-10-26 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
|
SG10201805674YA
(en)
*
|
2014-01-02 |
2018-08-30 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
WO2015135558A1
(en)
|
2014-03-12 |
2015-09-17 |
Curevac Gmbh |
Combination of vaccination and ox40 agonists
|
|
CA2945816A1
(en)
|
2014-04-15 |
2015-10-22 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
|
JP2017528143A
(ja)
*
|
2014-09-10 |
2017-09-28 |
ザ ユニバーシティ オブ コネチカット |
癌の治療のための免疫防御ネオエピトープ同定
|
|
AU2015315005B9
(en)
*
|
2014-09-10 |
2021-08-12 |
Genentech, Inc. |
Immunogenic mutant peptide screening platform
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
WO2016040900A1
(en)
*
|
2014-09-14 |
2016-03-17 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
HRP20211540T2
(hr)
*
|
2014-09-17 |
2022-05-13 |
Io Biotech Aps |
Sastavi cjepiva koji sadrže triptofan 2,3-dioksigenazu ili njene fragmente
|
|
SG11201702191YA
(en)
*
|
2014-09-17 |
2017-04-27 |
Univ Johns Hopkins |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
JP6599450B2
(ja)
|
2014-10-02 |
2019-10-30 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
JP6991857B2
(ja)
*
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
JP2018516847A
(ja)
*
|
2015-03-25 |
2018-06-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
生体高分子薬を送達するための組成物及び方法
|
|
US20190099475A1
(en)
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
CA3172682A1
(en)
|
2015-04-23 |
2016-10-27 |
Nantomics, Llc |
Cancer neoepitopes
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
HUE052106T2
(hu)
*
|
2015-04-27 |
2021-04-28 |
Cancer Research Tech Ltd |
Eljárás rák kezelésére
|
|
AU2016258845B2
(en)
|
2015-05-01 |
2022-03-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
IL293135A
(en)
|
2015-05-13 |
2022-07-01 |
Agenus Inc |
Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
|
|
MX2017014700A
(es)
*
|
2015-05-20 |
2018-08-15 |
Broad Inst Inc |
Neoantigenos compartidos.
|
|
TWI750122B
(zh)
*
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
EP3323070B1
(en)
|
2015-07-14 |
2024-05-08 |
Personal Genome Diagnostics Inc. |
Neoantigen analysis
|
|
MA42543A
(fr)
*
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
GB201516047D0
(en)
*
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
HK1258649A1
(zh)
*
|
2015-09-18 |
2019-11-15 |
Baylor College Of Medicine |
来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
MX2018004541A
(es)
*
|
2015-10-12 |
2019-04-15 |
Nantomics Llc |
Descubrimiento iterativo de neoepítopes e inmunoterapia adaptativa y método para ello.
|
|
AU2016339924B2
(en)
*
|
2015-10-12 |
2020-01-02 |
Nantomics, Llc |
Compositions and methods for viral cancer neoepitopes
|
|
EP3362930A4
(en)
|
2015-10-12 |
2019-06-19 |
Nantomics, LLC |
SYSTEMS, COMPOSITIONS, AND METHODS FOR DISCOVERING MSI AND NEOEPPITOPES THAT PROVIDE SENSITIVITY TO IMMUNE CONTROL POINTS
|
|
MX387275B
(es)
|
2015-10-12 |
2025-03-18 |
Nantomics Llc |
Neoepítopos virales y sus usos
|
|
MA46255A
(fr)
*
|
2015-10-22 |
2019-07-31 |
Modernatx Inc |
Vaccins anticancéreux
|
|
EP3371594A1
(en)
|
2015-11-06 |
2018-09-12 |
Ventana Medical Systems, Inc. |
Representative diagnostics
|
|
TWI733719B
(zh)
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
EP4299136A3
(en)
|
2015-12-16 |
2024-02-14 |
Gritstone bio, Inc. |
Neoantigen identification, manufacture, and use
|
|
CA3048202A1
(en)
*
|
2015-12-23 |
2017-06-29 |
Moonshot Pharma Llc |
Methods for inducing an immune response by inhibition of nonsense mediated decay
|
|
AU2017205270B2
(en)
|
2016-01-08 |
2024-01-18 |
Nykode Therapeutics ASA |
Therapeutic anticancer neoepitope vaccine
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
TW201739919A
(zh)
*
|
2016-02-12 |
2017-11-16 |
南坦生物組學有限責任公司 |
患者特異性新抗原決定基之高通量識別以作為用於癌症免疫療法之治療劑
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
US11585805B2
(en)
|
2016-02-19 |
2023-02-21 |
Nantcell, Inc. |
Methods of immunogenic modulation
|
|
JP2019513021A
(ja)
*
|
2016-03-24 |
2019-05-23 |
ナントセル，インコーポレイテッド |
ネオエピトープ提示のための配列の配置および配列
|
|
CA3056212A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene Corporation |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
WO2017180769A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
WO2018005276A1
(en)
*
|
2016-06-29 |
2018-01-04 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
CN115305229B
(zh)
|
2016-07-13 |
2025-08-19 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
|
KR102516166B1
(ko)
*
|
2016-07-20 |
2023-03-31 |
비온테크 에스이 |
향상된 효능을 갖는 치료를 위한 질병-특이적 표적으로서 네오에피토프의 선택
|
|
US20190167722A1
(en)
*
|
2016-08-02 |
2019-06-06 |
Nant Holdings Ip, Llc |
Transfection of dendritic cells and methods therefor
|
|
WO2018045249A1
(en)
*
|
2016-08-31 |
2018-03-08 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10463686B2
(en)
|
2016-09-15 |
2019-11-05 |
Idera Pharmaceuticals, Inc. |
Immune modulation with TLR9 agonists for cancer treatment
|
|
WO2018057447A1
(en)
*
|
2016-09-23 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
US20190240257A1
(en)
*
|
2016-10-13 |
2019-08-08 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
GB2604416B
(en)
*
|
2016-10-18 |
2023-03-15 |
Univ Minnesota |
Tumor infiltating lymphocytes and methods of therapy
|
|
WO2018089637A1
(en)
|
2016-11-11 |
2018-05-17 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
EP3548897A4
(en)
|
2016-12-01 |
2020-08-12 |
Nantomics, LLC |
PRESENTATION AND TREATMENT OF TUMOR ANTIGENICITY
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
BR112019015797A2
(pt)
*
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
KR20240117650A
(ko)
*
|
2017-02-01 |
2024-08-01 |
모더나티엑스, 인크. |
Rna 암 백신
|
|
JP2020514378A
(ja)
*
|
2017-03-20 |
2020-05-21 |
ジェノセア バイオサイエンシーズ， インコーポレイテッド |
処置方法
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
CA3058807A1
(en)
|
2017-04-03 |
2018-10-11 |
Neon Therapeutics, Inc. |
Protein antigens and uses thereof
|
|
AU2018250226B2
(en)
|
2017-04-04 |
2025-04-24 |
Barinthus Biotherapeutics North America, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
JP7217711B2
(ja)
*
|
2017-04-19 |
2023-02-03 |
グリットストーン バイオ インコーポレイテッド |
新生抗原の特定、製造、及び使用
|
|
US11779637B2
(en)
|
2017-04-24 |
2023-10-10 |
Nantcell, Inc. |
Targeted neoepitope vectors and methods therefor
|
|
AU2018266705B2
(en)
|
2017-05-08 |
2023-05-04 |
Seattle Project Corp. |
Alphavirus neoantigen vectors
|
|
US20200199660A1
(en)
|
2017-05-10 |
2020-06-25 |
The Broad Institute, Inc. |
Methods and compositions for determination of mutations in single replication events
|
|
US12226479B2
(en)
|
2017-05-11 |
2025-02-18 |
The General Hospital Corporation |
Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
WO2018223092A1
(en)
*
|
2017-06-02 |
2018-12-06 |
Arizona Board Of Regents On Behalf Of Arizona State University |
A method to create personalized cancer vaccines
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
SG11201912429RA
(en)
*
|
2017-06-21 |
2020-01-30 |
Transgene Sa |
Personalized vaccine
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
AU2018304543A1
(en)
|
2017-07-21 |
2020-02-13 |
Berkeley Lights, Inc. |
Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated T cells, and uses thereof
|
|
WO2019023269A1
(en)
|
2017-07-25 |
2019-01-31 |
California Institute Of Technology |
DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
EP3691676A4
(en)
*
|
2017-10-02 |
2021-06-16 |
Curematch, Inc. |
METHOD FOR PREDICTING ANTIGENICITY AND / OR IMMUNOGENICITY OF A TUMOR-DERIVED NEO-PEPTIDE, USING MUTATIONAL SIGNATURE GROUNDS
|
|
BR112020006879A2
(pt)
*
|
2017-10-06 |
2020-10-06 |
The Wistar Institute Of Anatomy And Biology |
composição para gerar um ou mais anticorpos anti-ctla-4 ou fragmentos dos mesmos em um sujeito, e, métodos para tratar uma doença em um sujeito e para aumentar uma resposta imune em um sujeito em necessidade do mesmo
|
|
EP3694532B1
(en)
|
2017-10-10 |
2025-02-26 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
JP7357613B2
(ja)
*
|
2017-11-06 |
2023-10-06 |
ラディック インスティテュート フォア キャンサー リサーチ リミテッド |
リンパ球の拡大方法
|
|
US20210154277A1
(en)
*
|
2017-11-07 |
2021-05-27 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
WO2019094642A1
(en)
|
2017-11-08 |
2019-05-16 |
Neon Therapeutics, Inc. |
T cell manufacturing compositions and methods
|
|
IL274799B2
(en)
|
2017-11-22 |
2025-05-01 |
Gritstone Bio Inc |
Reducing junction epitope presentation for neoantigens
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
CN118955720A
(zh)
|
2018-01-04 |
2024-11-15 |
伊科尼克治疗公司 |
抗组织因子抗体、抗体-药物缀合物及相关方法
|
|
US20210046177A1
(en)
|
2018-01-26 |
2021-02-18 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
WO2019147921A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
EP3759131A4
(en)
*
|
2018-02-27 |
2021-12-01 |
Gritstone bio, Inc. |
NEO-ANTIGEN IDENTIFICATION USING PAN-ALLEL MODELS
|
|
CN112218883A
(zh)
|
2018-04-26 |
2021-01-12 |
艾吉纳斯公司 |
热休克蛋白结合肽组合物及其使用方法
|
|
CA3100974A1
(en)
*
|
2018-05-25 |
2020-11-28 |
The Wistar Institute |
Tumor-specific neoantigens and methods of using the same
|
|
EP3806888B1
(en)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
BR112020025764A2
(pt)
|
2018-06-19 |
2021-05-11 |
Biontech Us Inc. |
neoantígenos e usos dos mesmos
|
|
US20220349010A1
(en)
*
|
2018-07-26 |
2022-11-03 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
IL321689A
(en)
|
2018-07-26 |
2025-08-01 |
Curevac Netherlands B V |
Vaccines against breast cancer
|
|
US20210252123A1
(en)
|
2018-07-26 |
2021-08-19 |
Frame Pharmaceuticals B.V. |
ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
|
|
EP3827266A1
(en)
|
2018-07-26 |
2021-06-02 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for uterine cancer
|
|
US20210213116A1
(en)
|
2018-07-26 |
2021-07-15 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
IL280115B2
(en)
|
2018-07-26 |
2025-11-01 |
Curevac Netherlands B V |
Cancer vaccines for colorectal cancer
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
CN112930569B
(zh)
|
2018-08-31 |
2025-10-03 |
夸登特健康公司 |
无细胞dna中的微卫星不稳定性检测
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
|
CA3112813A1
(en)
|
2018-09-21 |
2020-03-26 |
Berkeley Lights, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
IL281771B2
(en)
|
2018-09-27 |
2025-08-01 |
Nykode Therapeutics ASA |
Method for selecting neoepitopes
|
|
CN113272417A
(zh)
|
2018-10-18 |
2021-08-17 |
伯克利之光生命科技公司 |
原抗原呈递合成表面、活化的t细胞及其用途
|
|
CN113226359B
(zh)
|
2018-11-08 |
2024-05-24 |
耐克西缪恩有限公司 |
具有改进的表型特性的t细胞组合物
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
EP3927354A1
(en)
|
2019-02-20 |
2021-12-29 |
Rubius Therapeutics, Inc. |
Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
US20220130489A1
(en)
*
|
2019-03-12 |
2022-04-28 |
Syntekabio,Inc. |
System and method for providing neoantigen immunotherapy information by using artificial-intelligence-model-based molecular dynamics big data
|
|
CA3138867A1
(en)
*
|
2019-05-03 |
2020-11-12 |
Guilhem RICHARD |
Neoantigens in cancer
|
|
US20220220472A1
(en)
*
|
2019-05-06 |
2022-07-14 |
The Regents Of The University Of Michigan |
Targeted therapy
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
BR112021024127A2
(pt)
|
2019-05-30 |
2022-04-26 |
Gritstone Bio Inc |
Adenovírus modificado
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
WO2021230247A1
(ja)
*
|
2020-05-12 |
2021-11-18 |
大日本住友製薬株式会社 |
癌を処置するための医薬組成物
|
|
EP4149952A1
(en)
*
|
2020-05-12 |
2023-03-22 |
Institut Curie |
Neoantigenic epitopes associated with sf3b1 mutations
|
|
US20230210968A1
(en)
|
2020-06-11 |
2023-07-06 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
CN116438308A
(zh)
|
2020-08-06 |
2023-07-14 |
磨石生物公司 |
多表位疫苗盒
|
|
CA3189285A1
(en)
|
2020-08-13 |
2022-02-17 |
Vikram JUNEJA |
T cell manufacturing compositions and methods
|
|
GB2613718A
(en)
*
|
2020-08-31 |
2023-06-14 |
World Biotech Regenerative Medical Group Ltd |
Personalized immunogenic compositions and methods for producing and using same
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
US20240240259A1
(en)
*
|
2021-03-26 |
2024-07-18 |
The Translational Genomics Research Institute |
Methods and compounds for neoantigen vaccines
|
|
MX2023012698A
(es)
|
2021-04-30 |
2024-02-21 |
Tigen Pharma Sa |
Expansion de linfocitos en un solo recipiente.
|
|
US20230173046A1
(en)
*
|
2021-05-27 |
2023-06-08 |
Amazon Technologies, Inc. |
Multicomponent chemical composition of a peptide-based neoantigen vaccine
|
|
EP4392140A1
(en)
|
2021-08-24 |
2024-07-03 |
BioNTech SE |
In vitro transcription technologies
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
JP2025509607A
(ja)
|
2022-03-14 |
2025-04-11 |
ジェネレーション バイオ カンパニー |
異種プライムブーストワクチン組成物及び使用の方法
|
|
EP4598949A1
(en)
|
2022-10-07 |
2025-08-13 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
AU2023372974A1
(en)
|
2022-11-02 |
2025-06-12 |
Centre Hospitalier Universitaire Vaudois (Chuv) |
Expansion of lymphocytes
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|